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igration of Dendritic Cells from Blood to Tissues.
 
 A fun-
damental aspect of dendritic cell (DC) function is
their capacity to migrate. It allows them to exert a continu-
ous surveillance for incoming antigens in almost all body
tissues and a prompt report to T cells in secondary lym-
phoid organs. Under steady state conditions, the rate of DC
migration from blood to tissues and from tissues to lymph
nodes is probably very low, and most of these DCs reside
in the tissues in a dormant state ready to be activated by
pathogens. However, in inflammatory conditions the rate
of DC migration can be considerably increased to meet the
increased requirement for antigen presentation. Several re-
cent papers shed new light into the mechanisms that con-
trol the various steps that DCs have to undergo to perform
their function in the induction of tolerance, priming, and
chronic inflammation.
To exit from the blood stream DCs, like other leuko-
cytes, first need to tether to the endothelium (Fig. 1). This
process, which is essential for the subsequent steps of firm
adhesion and extravasation, is mediated by selectins that
bind to specific carbohydrates on specialized cell surface
molecules (1). In this issue, Robert et al. demonstrate that
DCs that circulate in peripheral blood express a glycosy-
lated form of P-selectin glycoprotein ligand (PSGL)-1 that
binds to P- and E-selectins, which are expressed at low lev-
els on endothelial cells and are upregulated by inflamma-
tory stimuli (2). Using an in vivo imaging system, they
show that DCs tether and roll on P- and E-selectins ex-
pressed by capillary endothelial cells and preferentially ex-
travasate at sites of inflammation. This novel finding indi-
cates that blood-borne DCs are poised to exit blood at
inflammatory sites, thus allowing rapid recruitment of these
APCs where their surveillance function is most needed.
Recruitment of leukocytes from blood to tissues is regu-
lated at the level of the endothelial cells, where inflammatory
cytokines increase the expression of adhesion molecules and
chemokines and induce the formation of Weibel-Palade bod-
ies. These represent storage granules for P-selectin (3, 4) and,
as shown in two recent papers, also for IL-8 (5, 6). The con-
tent of the Weibel-Palade bodies can be rapidly mobilized by
stimulation of endothelial cells with histamin or thrombin.
This mechanism can be viewed as a form of “memory,” since
it allows endothelial cells that had been exposed to inflamma-
tory stimuli to respond to a new challenge rapidly and with-
out need for new protein synthesis, which has clear physio-
logical as well as immunopathological significance.
A long-standing question has been the nature of the cir-
culating cells that give rise to tissue DCs. Are these the few
cells with DC phenotype characteristics that are present in
the blood stream, or are there more frequent precursors
that rapidly develop into DCs after entry into tissues?
Monocytes have been shown to exit blood (7), and repre-
sent nonproliferating precursors that differentiate in vitro to
immature DCs in cultures supplemented with GM-CSF
and IL-4 (8). The factors that may promote the monocyte
to DC transition in vivo still need to be defined. Recently,
Randolph et al. showed that in an in vitro culture system,
human peripheral blood monocytes cultured with endo-
thelial cells differentiate into DCs within 2 d, particularly
after phagocytosing particles in subendothelial collagen (9).
These DCs migrated back across the endothelium as they
Figure 1. Mobilization and activation of DCs control the induction of
tolerance, priming, and chronic inflammation. (A) Under steady state
conditions, the recruitment of DC precursors into tissues and the migra-
tion of mature DCs to lymph nodes occur at low rates. Tissue antigens
carried by short-lived migratory DCs may be transferred to resident lym-
phoid DCs that induce T cell tolerance. (B) Activated endothelial cells re-
cruit DCs at higher rates. Immature DCs are attracted by inflammatory
chemokines towards the site of inflammation, where bacterial and viral
products induce DC maturation and activation. In the lymph node, acti-
vated T cells can further enhance DC activation and survival via CD40L
and TRANCE. Because many and highly activated DCs are present, a
productive T cell response is induced. (C) Mature DCs that fail to migrate
to lymph nodes may serve as nucleation sites for chronic inflammatory re-
action. Chemokines produced by these DCs attract maturing DCs as well
as recently activated T cells, that maintain the inflammatory reaction.
Thick lines indicate activated cells. Mo, monocytes; iDC, immature DCs;
mDC, mature DCs; LyDC, lymphoid DCs. 
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would do during entry into lymphatics, while those that re-
mained in the subendothelial matrix became macrophages.
These results suggest that the interaction with endothelial
cells or extracellular matrix may be sufficient to drive dif-
ferentiation of monocytes to either DCs or macrophages,
each possessing inherently different migratory capacity. It
will be interesting to apply the in vivo imaging system used
by Robert et al. (2) to trace monocyte migration and dif-
ferentiation in vivo.
 
The Role of Chemokines in the Multistep Navigation of
DCs.
 
Chemokines play a role not only in the process of
extravasation, but also in the subsequent process of migra-
tion within the tissues to the final target. Different chemo-
kines provide codes for areas that are undergoing different
types of inflammatory reactions or are sites of constitutive
traffic (10, 11). A current view holds that the whole mi-
gration process occurs in distinct steps, each driven by a
particular chemokine–chemokine receptor pair (12). DCs
provide a striking example of this so-called multistep navi-
gation, since they use different sets of chemokine receptors
to migrate from blood to inflamed tissues and from there to
the lymphatics by which they reach their final destination
in the T cell areas of lymph nodes (Fig. 1).
Monocyte and monocyte-derived immature DCs ex-
press receptors for inflammatory chemokines such as
CCR1, CCR2, CCR5, and CXCR1, and are therefore
attracted to inflammatory sites where cognate ligands such
as IL-8, macrophage inflammatory protein (MIP)-1
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,
monocyte chemotactic protein (MCP)-1, and regulated
upon activation, normal T cell expressed and secreted
(RANTES) are produced (13, 14). Monocytes also express
CXCR4, which may be responsible for low level constitu-
tive recruitment by stromal cell–derived factor (SDF)-1
(13). In addition, immature DCs present in tonsils and in
cultures derived from CD34
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 progenitors express CCR6, a
receptor specific for liver and activation-regulated chemo-
kine (LARC)/MIP-3
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, which is produced in the crypts
of tonsils (15). Altogether it appears that inflammatory
chemokines guide the first step of DC migration from
blood into tissues and within tissues to inflammatory sites
where antigens must be captured.
Besides being attracted by inflammatory chemokines,
DCs also produce these chemokines in large amounts. The
production of inflammatory chemokines by DCs is rapidly
triggered after exposure to various maturation stimuli, and
has two major consequences. First, it enhances recruitment
of immature DCs, which is important to sustain antigen
sampling at later time points. Second, it downregulates the
expression of the cognate receptors on maturing DCs, thus
allowing them to leave the inflamed tissues (13).
The second step of DC migration, from inflamed tissues
into lymphatics and from there to T cell areas of lymph
nodes, is regulated by a different set of chemokines. Matur-
ing DCs upregulate receptors for constitutive chemokines
such as CXCR4, CCR4, and especially CCR7 (13–15).
CCR7 recognizes secondary lymphoid tissue chemokine
(SLC), produced by lymphatic endothelial cells (16), and
Epstein-Barr virus–induced molecule 1 ligand chemokine
 
(ELC), produced in the T cell areas by mature DCs (13,
15, 17), and therefore appears to be a key receptor for this
second step of directional migration (Fig. 1).
Although at early time points after induction of matura-
tion DCs are abundant sources of inflammatory chemo-
kines, at later time points mature DCs produce high levels
of constitutive chemokines such as thymus and activation-
regulated chemokine (TARC), macrophage-derived chemo-
kine (MDC), and ELC (F. Sallusto, unpublished data). This
allows mature DCs, once they reach the T cell areas, to
attract other maturing DCs as well as naive and recently ac-
tivated T cells that express the cognate receptors CCR7
and CCR4 (for a review, see reference 18). Therefore,
chemokine production by mature DCs plays an important
function in organizing T cell areas and lymph node structure.
 
Migration of Stimulatory or Tolerizing DCs.
 
Antigen pre-
sentation can lead either to full activation and priming of
effector and memory T cells or to an abortive stimulation,
resulting in functional inactivation and T cell tolerance.
Finding the factors that regulate the balance between toler-
ance and response is now considered the holy grail of im-
munology. The current view is that the critical factor lies in
the nature of the APC: mature DCs prime, whereas resting
B cells and tissue cells tolerize. This notion has been re-
cently challenged by Kurts and colleagues (19). These au-
thors show that, in the absence of inflammation, a model
antigen expressed in tissue cells is presented by bone mar-
row–derived APCs on class I molecules in the draining
lymph node. Strikingly, this presentation results in transient
CD8 T cell proliferation, which leads to tolerance. These
observations imply that migratory, bone marrow–derived
APCs (most likely DCs) pick up antigen in noninflamed
tissues and migrate at low rate to the lymph nodes to in-
duce tolerance to tissue antigens. At odds with the current
view, the findings by Kurts et al. suggest that DCs are re-
sponsible not only for priming, but also for tolerance.
Two mechanisms may account for this striking finding.
The first possibility is that the tolerogenic DCs represent a
specialized lineage. A likely candidate is the lymphoid DC
described by Shortman and colleagues, which can stimulate
T cells but appears to be unable to support IL-2 production
(20). If distinct DC subsets are involved in induction of tol-
erance or response, it will be important to assess whether
they are recruited in response to different stimuli. For in-
stance, tolerogenic DCs may be mobilized constitutively,
whereas the stimulatory DC lineage may be preferentially
recruited under inflammatory conditions. Recently, Inaba
and colleagues showed that antigens carried by short-lived
migratory DCs can be transferred to lymph node–resident,
most likely lymphoid DCs (21; Fig. 1). They suggested
that, in the absence of inflammation, this mechanism may
be responsible for the induction of tolerance to tissue anti-
gens, thus accounting for the observation of Kurts et al. (19).
The second possibility is that the same DC type is re-
sponsible for inducing either tolerance or response, de-
pending on several factors such as the number of DCs that
reach the lymph node, their life span, and the nature and
amount of costimulatory molecules and cytokines they ex- 
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press. These factors will be determined by the context in
which DCs are stimulated to mature. Bacterial and viral
products such as LPS and double-stranded (ds)RNA recruit
large numbers of DCs and activate them to a high stimula-
tory status, whereas endogenous inflammatory cytokines
are much less effective (22–24). CD40L and TNF–related
activation-induced cytokine (TRANCE) represent addi-
tional endogenous stimuli by which T cells can enhance
DC stimulatory capacity (25–27) and viability. According
to the second DC activation hypothesis, tolerance or prim-
ing will be determined by how far pathogens and/or mem-
ory T cells raise the activation state of maturing DCs, i.e.,
high activation state and high numbers will favor priming,
whereas low activation and low numbers will induce toler-
ance or ignorance (Fig. 1). The regulatory role of patho-
gens, antigen dose, and kinetics of presentation has been
amply documented (28). There is now growing evidence
that most of this regulation is taking place primarily at the
level of DCs.
 
A Role for DCs in Chronic Inflammation.
 
A long-stand-
ing observation has been that tissues undergoing chronic
inflammatory reactions contain infiltrates of lymphocytes
that are organized in lymph node–like structures. TNF-
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and lymphotoxin (LT) are required for this lymphoid neo-
genesis (29), and recent data suggest that DCs might also
play a role in maintaining chronic inflammation via de
novo formation of local lymphoid tissue. Ludewig et al.
showed that repetitive immunization with DCs carrying a
diabetogenic peptide induced chronic inflammation and
lymphoid neogenesis, demonstrating that DCs presenting
self-antigens are not only potent inducers of autoreactive T
cells, but also help to maintain a peripheral immune re-
sponse locally (30). It will be important to consider this as a
potential hazard in DC-based antitumor therapies.
Based on the central role played by chemokines, it is
tempting to suggest that DCs that mature in inflamed tis-
sues and fail to migrate to the lymph nodes may act as nu-
cleation sites to organize a lymphoid structure that sustains
the chronic inflammatory reaction (Fig. 1). Indeed, ma-
ture DCs produce constitutive chemokines such as ELC,
TARC, and MDC which attract recently activated T cells
that have upregulated CCR7 and CCR4 as well as matur-
ing DCs that may sustain the process of lymphoid neogen-
esis. This mechanism may explain why sites of chronic in-
flammation such as the rheumatoid arthritis synovia can act
as sinks for recently activated T cells such as those that are
chronically activated by endogenous antigens, for instance
EBV (31). Although these cells are not autoreactive, they
may nonetheless aggravate the chronic inflammatory pro-
cess. For example, they could be activated in an antigen-
independent fashion by certain cytokine combinations pre-
sent in the microenvironment (32), and in this way may
provide to DC survival and activation signals (via CD40L
and TRANCE) that may be important to sustain the in-
flammatory process.
As our understanding of DC physiology improves, we
realize that we cannot look at these cells simply as the
“good guys.” Because of their fundamental role in initiat-
ing T cell responses, it is perhaps not surprising that they
are involved in many aspects of immune regulation, includ-
ing tolerance and autoimmunity. Understanding the con-
trol of DC traffic and activation will provide new avenues
for therapeutic intervention.
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